Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05LCN
|
|||
| Former ID |
DIB007822
|
|||
| Drug Name |
BMP-7 bone morphogenetic protein
|
|||
| Synonyms |
BMP-2; BMP-7; Vascular calcification therapeutics, Johnson & Johnson; BMP-7 (kidney disease), Curis; BMP-7 (kidney disease), Stryker; Bone morphogenetic protein (BioChaperone technology, bone repair), Adocia; Bone morphogenetic protein (BioChaperone technology, degenerative disc disease/spinal fusion),Adocia; Bone morphogenic protein modulators (renal osteodystrophy/ vascular calcification), Johnson & Johnson; BMP-based therapeutics (renal osteodystrophy/ vascular calcification), Johnson & Johnson; BMP-based therapeutics (renal osteodystrophy/ vascular calcification), Ortho Biotech/Centocor
Click to Show/Hide
|
|||
| Indication | Kidney disease [ICD-11: GC2Z] | Phase 4 | [1], [2] | |
| Company |
Curis Inc; Adocia SAS
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4886). | |||
| REF 2 | ClinicalTrials.gov (NCT00551941) A Prospective Randomized Controlled Trial on the Use of Bone Morphogenetic 7 (BMP-7) (OP-1) and Demineralized Bone Matrix in Tibial Non-union. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.